
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is a leading radiopharmaceutical company that has a unique technology utilizing the alpha-emitting isotope Lead-212 to target and treat cancer cells with minimal side effects, making it a promising treatment option in the evolving NET treatment paradigm. With positive updated data from its Phase 1/2a study of VMT-α-NET at AACR 2026, including an overall response rate of 60% and an excellent safety profile, the company is well-positioned for continued success in clinical trials and potential commercialization. However, there are risks to consider, such as competition and potential challenges with reimbursement and adoption.
Bears say
Perspective Therapeutics is a clinical stage biotech company with a proprietary technology for delivering radiation to cancer cells, but their current pipeline lacks solid data and precise targeting moieties. Additionally, their aggressive dosing approach may compromise efficacy and the company's high valuation can be considered overvalued considering their limited clinical progress and lack of commercial success.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares